Plozasiran Drug Asset Due Diligence Report 2026

This Plozasiran Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Plozasiran can convert its siRNA profile and APOC3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Plozasiran (query alias: plozasiran)
Modality / target	siRNA; APOC3; APOC3 inhibitors, RNAi
Highest global status	Approved
Originator	Arrowhead Pharmaceuticals, Inc.
Active developers	Arrowhead Pharmaceuticals, Inc., Wei Ya Zhen Sheng Wu Ji Shu （ Su Zhou ） You Xian Gong Si, Sanofi (China) Investment Co. Ltd.

The MCP disease footprint includes Hypertriglyceridemia, Familial chylomicronaemia syndrome, Hyperlipoproteinemia Type I. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06822790	Phase 3	Recruiting	869	Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
NCT06347016	Phase 3	Active, not recruiting	311	Percent change in fasting serum TG levels from baseline to Month 12 compared to placebo
NCT06880770	Phase 3	Recruiting	288	Time to First Occurrence of Positively Adjudicated AP Event (Event Occurring More Than 10 Days After First Dose of Study Drug)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia—Results of a Post Hoc Analysis of the Phase 3 <scp>PALISADE</scp> Study

Phase 3; n=67; evaluation: Positive. Reported fields: AP = 5.0 Pts ; AP = 2.0 Pts

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Phase 2; n=229; evaluation: not stated. Reported fields: Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG)(Least Squares Mean): Difference = -48.8(95% CI, -64.0 to -33.7), P-Value = < 0.0001; Difference = -53.1(95% CI, -68.1 to -38.0), P-Value = < 0.0001; Difference = -57.0(95% CI, -71.9 to -42.1), P-Value = < 0.0001; Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG)(Least Squares Mean) = -74.2 percentage change (Standard Error, 5.44); Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG)(Least Squares Mean): Difference = -48.8(95% CI, -64.0 to -33.7), P-Value = < 0.0001; Difference = -53.1(95% CI, -68.1 to -38.0), P-Value = < 0.0001; Difference = -57.0(95% CI, -71.9 to -42.1), P-Value = < 0.0001

A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 / VSA001 / SAR449124 Injection in Chinese Adults With Familial Chylomicronemia Syndrome

Phase 3; n=37; evaluation: not stated. Reported fields: Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10(Median) = 38.8 Percent change (Full Range, -56.2 to 136.7); Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10(Median) = -89.5 Percent change (Full Range, -94.7 to -18.1); Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10(Median): Median Difference (Final Values) = -101.7(95% CI, -167.8 to -35.5), P-Value = 0.0022; Median Difference (Final Values) = -103.2(95% CI, -168.9 to -37.5), P-Value = 0.0022

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Plozasiran addresses Hypertriglyceridemia, Familial chylomicronaemia syndrome, Hyperlipoproteinemia Type I. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—siRNA—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-02-10	Vanscoy Rare Pharmacy Selected as Exclusive Distribution Pharmacy for Redemplo® (plozasiran) for adults with Familial Chylomicronemia Syndrome (FCS)	Approved	Financial terms not disclosed
2025-08-01	Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi	NDA/BLA	US$130.0M upfront; US$265.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO